Aralez pharmaceuticals inc. (ARLZ)
Balance Sheet / Quarterly
Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15
ASSETS
Current assets:
Cash and cash equivalents

43,887

28,892

40,731

55,776

73,729

64,943

56,533

93,032

114,026

24,816

Accounts receivable, net

40,680

13,453

11,336

9,548

9,048

20,405

8,109

7,113

11,561

5,966

Inventory

5,672

6,643

4,920

4,994

4,132

4,548

-

-

-

-

Inventory

-

-

-

-

-

-

4,735

4,863

4,428

-

Prepaid expenses and other current assets

3,067

3,687

3,325

4,164

4,774

2,435

2,965

2,888

3,681

1,225

Total current assets

93,306

52,675

60,312

74,482

91,683

92,331

72,342

107,896

133,696

32,007

Property and equipment, net

6,603

7,453

7,715

8,061

8,172

7,316

2,527

2,166

1,331

251

In-process research and development

-

-

-

-

-

-

-

-

3,469

-

Goodwill

79,683

81,781

82,184

79,202

77,384

76,694

77,039

74,485

74,465

-

Other intangible assets, net

299,610

310,346

319,324

325,359

332,306

340,194

127,724

90,505

87,884

-

Other long-term assets

1,976

1,222

1,732

1,409

1,017

842

686

697

-

-

Total assets

481,178

453,477

471,267

488,513

510,562

517,377

280,318

275,749

300,845

32,258

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable

10,587

23,631

22,145

24,494

25,942

8,833

1,965

2,534

6,204

4,557

Accrued compensation

-

-

-

-

-

-

-

-

5,566

-

Accrued expenses

89,876

28,496

26,046

28,916

26,275

32,141

23,557

17,624

11,240

11,932

Short-term contingent consideration

10,460

11,482

8,930

9,151

10,266

10,430

600

-

-

-

Note payable

-

-

-

-

-

-

-

-

3,855

-

Other current liabilities

5,901

4,251

3,223

4,268

6,288

5,870

3,993

4,322

7,787

-

Total current liabilities

116,824

67,860

60,344

66,829

68,771

57,274

30,115

24,480

34,652

16,489

Long-term debt, net

274,573

274,546

274,520

274,494

274,467

274,441

74,520

-

-

-

Deferred tax liability

2,545

3,797

3,522

3,386

3,305

3,273

-

-

-

-

Long-term contingent consideration

90,781

88,873

70,559

65,815

65,167

60,685

18,900

-

-

-

Long-term debt, net

-

-

-

-

-

-

-

74,498

74,476

-

Deferred tax liability

-

-

-

-

-

-

6,064

6,490

7,395

-

Other long-term liabilities

3,034

3,182

3,201

2,962

2,630

2,218

171

562

446

986

Total liabilities

487,757

438,258

412,146

413,486

414,340

397,891

129,770

106,030

116,969

17,475

Commitments and Contingencies

0

0

0

0

0

0

0

0

0

0

Preferred shares, no par value; unlimited shares authorized, issuable in series; none outstanding

0

0

0

0

0

0

0

0

0

0

Common shares, no par value, unlimited shares authorized, 67,194,277 and 66,972,742 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively

0

0

0

0

0

0

-

-

-

33

Additional paid-in capital

365,608

363,792

361,181

358,221

355,268

352,336

349,013

345,523

342,652

149,438

Accumulated other comprehensive income

10,443

14,298

15,044

9,469

6,097

4,816

8,085

10,147

9,700

-

Accumulated deficit

-382,630

-362,871

-317,104

-292,663

-265,143

-237,666

-206,550

-185,951

-168,476

-134,688

Total shareholders (deficit) equity

-6,579

15,219

59,121

75,027

96,222

119,486

150,548

169,719

183,876

14,783

Total liabilities and shareholders equity

481,178

453,477

471,267

488,513

510,562

517,377

280,318

275,749

300,845

32,258